Your browser doesn't support javascript.
loading
Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico.
Romero-Ibarguengoitia, Maria Elena; Rivera-Salinas, Diego; Sarti, Riccardo; Levi, Riccardo; Mollura, Maximiliano; Garza-Silva, Arnulfo; Rivera-Cavazos, Andrea; Hernández-Ruíz, Yodira Guadalupe; Barco-Flores, Irene Antonieta; González-Cantú, Arnulfo; Sanz-Sánchez, Miguel Ángel; Guimarães Júnior, Milton Henriques; Pozzi, Chiara; Barbieri, Riccardo; Morales-Rodriguez, Devany Paola; Texeira, Mauro Martins; Rescigno, Maria.
Afiliação
  • Romero-Ibarguengoitia ME; Research Department, Hospital Clínica Nova de Monterrey, San Nicolas de los Garza 66450, Nuevo Leon, Mexico.
  • Rivera-Salinas D; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, Nuevo Leon, Mexico.
  • Sarti R; Research Department, Hospital Clínica Nova de Monterrey, San Nicolas de los Garza 66450, Nuevo Leon, Mexico.
  • Levi R; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, Nuevo Leon, Mexico.
  • Mollura M; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
  • Garza-Silva A; IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
  • Rivera-Cavazos A; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
  • Hernández-Ruíz YG; IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
  • Barco-Flores IA; Politecnico di Milano, Department of Electronic, Information and Bioengineering, 20133 Milan, Italy.
  • González-Cantú A; Research Department, Hospital Clínica Nova de Monterrey, San Nicolas de los Garza 66450, Nuevo Leon, Mexico.
  • Sanz-Sánchez MÁ; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, Nuevo Leon, Mexico.
  • Guimarães Júnior MH; Research Department, Hospital Clínica Nova de Monterrey, San Nicolas de los Garza 66450, Nuevo Leon, Mexico.
  • Pozzi C; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, Nuevo Leon, Mexico.
  • Barbieri R; Research Department, Hospital Clínica Nova de Monterrey, San Nicolas de los Garza 66450, Nuevo Leon, Mexico.
  • Morales-Rodriguez DP; Research Department, Hospital Clínica Nova de Monterrey, San Nicolas de los Garza 66450, Nuevo Leon, Mexico.
  • Texeira MM; Research Department, Hospital Clínica Nova de Monterrey, San Nicolas de los Garza 66450, Nuevo Leon, Mexico.
  • Rescigno M; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, Nuevo Leon, Mexico.
Vaccines (Basel) ; 11(4)2023 Apr 14.
Article em En | MEDLINE | ID: mdl-37112754
Comparisons among the different vaccines against SARS-CoV-2 are important to understand which type of vaccine provides more protection. This study aimed to evaluate the real-life efficacy through symptomatic infection and the humoral response of six different vaccines against SARS-CoV-2-BNT162b2, mRNA-1273, ChAdOx1-S, CoronaVac, Ad26.COV2, and Ad5-nCoV. This multicentric observational longitudinal study involved hospitals from Mexico and Brazil in which volunteers who received complete vaccination schemes were followed for 210 days after the last dose. SARS-CoV-2 Spike 1-2 IgG levels were taken before receiving the first vaccine, 21 days after each dose, and the last sample at six months (+/-1 month) after the last dose. A total of 1132 individuals exposed to five COVID-19 waves were included. All vaccines induced humoral responses, and mRNA vaccines had the highest antibody levels during follow-up. At six months, there was a decline in the SARS-CoV-2 Spike 1-2 IgG antibody titers of 69.5% and 36.4% in subjects with negative and positive history of infection respectively. Infection before vaccination and after complete vaccination scheme correlated with higher antibody titers. The predictors of infection were vaccination with CoronaVac compared to BNT162b2 and ChAdOx1-S. In the presence of comorbidities such as diabetes, rheumatoid arthritis, or dyslipidemia, CoronaVac lowered the risk of infection.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Região como assunto: America do sul / Brasil / Mexico Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: México País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Região como assunto: America do sul / Brasil / Mexico Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: México País de publicação: Suíça